National Institutes of Health (NIH) Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding  
6/11/2010 9:13:15 AM

WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) announced today that human embryonic stem cell (hESC) line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director (ACD) National Institutes of Health (NIH). In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH. Five of these lines were produced without embryo destruction using ACT’s proprietary single-blastomere “embryo-safe” technology. The federal funding could accelerate the company’s clinical activities.